세계의 호흡기계 약물 전달 시장(2024-2034년)

Respiratory Drug Delivery Market Report 2024-2034

￡ 4,350 ￦ 8,365,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. PDF 내 텍스트 등의 복사 및 붙여넣기, 인쇄 불가능합니다.

￡ 5,150 ￦ 9,904,000

PDF (Team License - Up to 6 Users)

PDF 보고서를 동일 사업장(소재지) 내 최대 6명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 6,050 ￦ 11,635,000

PDF (Site License)

PDF 보고서를 동일 사업장(소재지) 내 최대 6명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 7,645 ￦ 14,702,000

PDF (Enterprise License - Includes Free Datasets)

PDF 보고서를 동일 사업장(소재지)의 모든 분이 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 호흡기계 약물 전달 시장 규모는 2034년까지 연평균 복합 성장률(CAGR) 7.8%로 성장할 것으로 예상됩니다.

스마트/디지털 흡입기 출시와 코로나19 사태가 산업 성장을 가속할 것으로 예상됩니다. 반면, 엄격한 정부 규제가 업계 성장에 걸림돌이 될 것으로 보입니다.

세계 호흡기계 약물 전달(Respiratory Drug Delivery) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• SWOT 분석
• PEST 분석

제4장 호흡기계 약물전달 시장 분석 : 제품별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 제제
• 디바이스
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 호흡기계 약물전달 시장 : 제제별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 드라이 파우더 제제
• 현탁 에어로졸
• 용액 에어로졸
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 호흡기계 약물전달 시장 : 디바이스별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 정량 흡입기(MDI)
• 드라이 파우더 흡입기(DPI)
• 네뷸라이저
• 부속품
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 호흡기계 약물전달 시장 : 네뷸라이저별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 소프트 미스트 네뷸라이저
• 제트 네뷸라이저
• 초음파 네뷸라이저
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 호흡기계 약물전달 시장 : 캐니스터별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 플레인 캐니스터
• 코팅 캐니스터
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제9장 호흡기계 약물전달 시장 : 용도별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 천식
• 만성 폐쇄성 폐질환(COPD)
• 낭포성 섬유증
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제10장 호흡기계 약물전달 시장 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 홈케어
• 병원 및 클리닉
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제11장 호흡기계 약물전달 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제12장 북미의 호흡기계 약물전달 시장 분석

제13장 유럽의 호흡기계 약물전달 시장 분석

제14장 아시아태평양의 호흡기계 약물전달 시장 분석

제15장 라틴아메리카의 호흡기계 약물전달 시장 분석

제16장 중동 및 아프리카의 호흡기계 약물전달 시장 분석

제17장 기업 개요

• 경쟁 구도
• GSK plc
• Koninklijke Philips N.V.
• 3M
• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck &Co., Inc.
• Novartis AG
• Omron Corporation
• Sumitomo Pharma Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Medisana GmbH
• GF Health Products, Inc.
• AptarGroup, Inc.
• Recipharm AB
• Glenmark Pharmaceuticals Ltd.
• Vapotherm, Inc.

제18장 결론 및 추천 사항

• Visiongain의 결론
• 참여 기업을 위한 추천 사항

LSH

영문 목차

영문목차

The global Respiratory Drug Delivery market is projected to grow at a CAGR of 7.8% by 2034.

“The Respiratory Drug Delivery Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Launch of Smart/Digital Inhalers and Outbreak of COVID-19 Pandemic Projected to Spur Industry Growth

At present, smart inhalers just record the patient's actuation, which is a time and date stamp, during use. Numerous firms are producing devices that can be connected to inhalers that are currently in use. Leading the way in this trend are the American organisations Propeller Health and Adherium, both of which were founded in New Zealand. Data from clinical studies conducted by both firms indicate that patients might gain advantages from utilising their products. In another instance, Innovate UK provided co-funding to Aseptika, a firm that specialises in developing intelligent inhalers for patients with chronic respiratory conditions, in January 2023. With integrated 5G mobile connectivity, the company's third-generation smart inhaler tracker will be developed further with the help of the Smart Award.

Since COVID-19 affects particular lung tissues, bronchodilators are frequently utilised as part of therapy. Nebulizers may encourage the creation of aerosolized virus in patients, which could worsen the spread of COVID-19. For this reason, the use of MDI is advised. There is a growing medical need for COVID-19 treatment, which is creating a shortage of inhalers. For instance, a strategic agreement was reached in October 2022 between GenScript ProBio and Hibiocy Co. Ltd. to accelerate the development of COVITRAP, a respiratory-care medical device that includes a human antibody for COVID-19. By preventing the COVID-19 virus from sticking to the nasal cavity's interior surfaces, COVITRAP, a nasal spray, can reduce the amount of virus present in the nasal cavity. Following approval by the Thai FDA, COVITRAP was formally released onto the Thai market. This indicates that in reaction to the COVID-19 pandemic, there has been an increased demand for respiratory medicine delivery technologies to treat patients with the virus as well as those suffering from bronchitis, asthma, and other respiratory conditions.

Stringent Government Regulations Likely to Challenge Industry Growth

The FDA usually goes through lengthy and laborious processes to approve medical devices, drugs, and drug technology before a product can be sold. This usually poses a challenge to companies that conduct intensive R&D in order to launch new products on the market. Authorities rigorously verify the product's safety and use before making it available for sale to the general public. As a drug-device combination of 97 items, MDIs and DPIs are mixed products subject to the current good manufacturing practice (CGMP) requirements for pharmaceuticals and devices. In particular, they apply to all MDIs and DPIs that have a device component that is subject to design controls (21 CFR 820.30). Industry guidelines on pharmaceutical development, which are founded on the concepts of quality via design, address the processes of product design and development. Even though quality via 110 design and design controls have the same features and objectives, the Quality System 111 Regulation (21 CFR 820) for devices provides design requirements.

What Questions Should You Ask Before Buying a Market Research Report?

• How is the respiratory drug delivery market evolving?
• What is driving and restraining the respiratory drug delivery market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each respiratory drug delivery submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading respiratory drug delivery markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the respiratory drug delivery projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of respiratory drug delivery projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the respiratory drug delivery market?
• Where is the respiratory drug delivery market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Respiratory Drug Delivery market today, and over the next 10 years:

• Our 348-page report provides 147 tables, 249 charts, and graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the respiratory drug delivery market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising respiratory drug delivery prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product

• Formulations
• Devices

Formulations

• Dry Powder
• Suspension Aerosol
• Solution Aerosol

Devices

• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Nebulizers
• Accessories

Nebulizers

• Soft Mist Nebulizers
• Jet Nebulizers
• Ultrasonic Nebulizers

Canister

• Plain Canisters
• Coated Canister

Application

• Asthma
• COPD
• Cystic Fibrosis
• Others

End-users

• Homecare settings
• Hospitals & Clinics
• Other End-users

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Switzerland
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Egypt
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Respiratory Drug Delivery Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report:

Overall world revenue for Respiratory Drug Delivery Market, 2024 to 2034 in terms of value the market will surpass US$67.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Respiratory Drug Delivery Market, 2024 to 2034” report help you?

In summary, our 340+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Respiratory Drug Delivery Market, 2024 to 2034, with forecasts for product, formulations, devices, nebulizers, canister, application and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Respiratory Drug Delivery Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Russia, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Respiratory Drug Delivery Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the respiratory drug delivery Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Respiratory Drug Delivery Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.2 Technological Advancements in Respiratory Drug Delivery Expected to Boost the Market
    • 3.2.1.3 Outbreak of COVID-19 Pandemic
    • 3.2.1.4 Growing Support of Government and NGOs for Respiratory Diseases Healthcare Awareness
    • 3.2.1.5 Launch of Smart/Digital Inhalers will Propel the Adoption of Advanced Drug Delivery Devices
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Stringent Government Regulations is Expected to Hinder the Market Growth
    • 3.2.2.2 Intense Competition Among Vendors is Projected to Restrain the Market Growth
    • 3.2.2.3 Pricing Pressure a Major Challenge
    • 3.2.2.4 Challenges Associated with Respiratory Drugs Delivery Design
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Trends in Metered Dose Inhaler (MDI) Technology is Expected to Propel the Market in Near Future
    • 3.2.3.2 Mergers, Agreements, and Acquisitions by Market Players is a Major Trend Witnessed in the Market
    • 3.2.3.3 Dry Powder Drug Delivery Product Innovation Driving the Adoption of Respiratory Drugs
    • 3.2.3.4 Increase in Research and Development in Pulmonary Drug Delivery System
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Supplier: High
  • 3.4.2 Threat of New Entrants: Moderate
  • 3.4.3 Bargaining Power of Buyer: Moderate
  • 3.4.4 Competitive Rivalry: High
  • 3.4.5 Threat of Substitutes: Moderate
• 3.5 SWOT Analysis
• 3.6 PEST Analysis
  • 3.6.1 Political Factors Impacting Respiratory Drug Delivery Market
  • 3.6.2 Economic Factors Impacting Respiratory Drug Delivery Market
  • 3.6.3 Social Factors Impacting Respiratory Drug Delivery Market
  • 3.6.4 Technological Factors Impacting Respiratory Drug Delivery Market

4 Respiratory Drug Delivery Market Analysis by Product

• 4.1 Key Findings
• 4.2 Product Segment: Market Attractiveness Index
• 4.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 4.4 Formulations
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Devices
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Respiratory Drug Delivery Market by Formulations

• 5.1 Key Findings
• 5.2 Formulations Segment: Market Attractiveness Index
• 5.3 Respiratory Drug Delivery Market, by Formulations
• 5.4 Dry Powder Formulation
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Suspension Aerosol
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Solution Aerosol
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Respiratory Drug Delivery Market by Devices

• 6.1 Key Findings
• 6.2 Devices Segment: Market Attractiveness Index
• 6.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 6.4 Metered Dose Inhalers (MDIs)
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Dry Powder Inhalers (DPIs)
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Nebulizers
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)
• 6.7 Accessories
  • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Respiratory Drug Delivery Market by Nebulizers

• 7.1 Key Findings
• 7.2 Nebulizers Segment: Market Attractiveness Index
• 7.3 Respiratory Drug Delivery Market by Nebulizers Forecast, 2024-2034
• 7.4 Soft Mist Nebulizers
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Jet Nebulizers
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 Ultrasonic Nebulizers
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Respiratory Drug Delivery Market by Canister

• 8.1 Key Findings
• 8.2 Canister Segment: Market Attractiveness Index
• 8.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 8.4 Plain canisters
  • 8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 8.4.2 Market Share by Region, 2024 & 2034 (%)
• 8.5 Coated canisters
  • 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 8.5.2 Market Share by Region, 2024 & 2034 (%)

9 Respiratory Drug Delivery Market by Application

• 9.1 Key Findings
• 9.2 Application Segment: Market Attractiveness Index
• 9.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 9.4 Asthma
  • 9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 9.4.2 Market Share by Region, 2024 & 2034 (%)
• 9.5 Chronic Obstructive Pulmonary Disease (COPD)
  • 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 9.5.2 Market Share by Region, 2024 & 2034 (%)
• 9.6 Cystic Fibrosis
  • 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 9.6.2 Market Share by Region, 2024 & 2034 (%)
• 9.7 Others
  • 9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 9.7.2 Market Share by Region, 2024 & 2034 (%)

10 Respiratory Drug Delivery Market by End-users

• 10.1 Key Findings
• 10.2 End-users Segment: Market Attractiveness Index
• 10.3 Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 10.4 Homecare Settings
  • 10.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 10.4.2 Market Share by Region, 2024 & 2034 (%)
• 10.5 Hospital & Clinics
  • 10.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 10.5.2 Market Share by Region, 2024 & 2034 (%)
• 10.6 Other End-users
  • 10.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 10.6.2 Market Share by Region, 2024 & 2034 (%)

11 Respiratory Drug Delivery Market Analysis by Region

• 11.1 Key Findings
• 11.2 Regional Market Size Estimation and Forecast

12 North America Respiratory Drug Delivery Market Analysis

• 12.1 Key Findings
• 12.2 North America Respiratory Drug Delivery Market Attractiveness Index
• 12.3 North America Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Country
• 12.5 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 12.6 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
• 12.7 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 12.8 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 12.9 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 12.10 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
• 12.11 North America Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 12.12 U.S. Respiratory Drug Delivery Market Analysis
• 12.13 Canada Respiratory Drug Delivery Market Analysis

13 Europe Respiratory Drug Delivery Market Analysis

• 13.1 Key Findings
• 13.2 Europe Respiratory Drug Delivery Market Attractiveness Index
• 13.3 Europe Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 13.4 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Country
• 13.5 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 13.6 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
• 13.7 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 13.8 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 13.9 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 13.10 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
• 13.11 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 13.12 Germany Respiratory Drug Delivery Market Analysis
• 13.13 UK Respiratory Drug Delivery Market Analysis
• 13.14 France Respiratory Drug Delivery Market Analysis
• 13.15 Italy Respiratory Drug Delivery Market Analysis
• 13.16 Spain Respiratory Drug Delivery Market Analysis
• 13.17 Switzerland Respiratory Drug Delivery Market Analysis
• 13.18 Russia Respiratory Drug Delivery Market Analysis
• 13.19 Rest of Europe Respiratory Drug Delivery Market Analysis

14 Asia Pacific Respiratory Drug Delivery Market Analysis

• 14.1 Key Findings
• 14.2 Asia Pacific Respiratory Drug Delivery Market Attractiveness Index
• 14.3 Asia Pacific Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 14.4 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Country
• 14.5 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 14.6 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
• 14.7 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 14.8 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 14.9 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 14.10 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
• 14.11 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 14.12 Japan Respiratory Drug Delivery Market Analysis
• 14.13 China Respiratory Drug Delivery Market Analysis
• 14.14 India Respiratory Drug Delivery Market Analysis
• 14.15 Australia Respiratory Drug Delivery Market Analysis
• 14.16 South Korea Respiratory Drug Delivery Market Analysis
• 14.17 South East Asia Respiratory Drug Delivery Market Analysis
• 14.18 Rest of Asia Pacific Respiratory Drug Delivery Market Analysis

15 Latin America Respiratory Drug Delivery Market Analysis

• 15.1 Key Findings
• 15.2 Latin America Respiratory Drug Delivery Market Attractiveness Index
• 15.3 Latin America Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 15.4 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Country
• 15.5 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 15.6 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
• 15.7 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 15.8 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 15.9 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 15.10 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
• 15.11 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 15.12 Brazil Respiratory Drug Delivery Market Analysis
• 15.13 Mexico Respiratory Drug Delivery Market Analysis
• 15.14 Argentina Respiratory Drug Delivery Market Analysis
• 15.15 Rest of Latin America Respiratory Drug Delivery Market Analysis

16 MEA Respiratory Drug Delivery Market Analysis

• 16.1 Key Findings
• 16.2 MEA Respiratory Drug Delivery Market Attractiveness Index
• 16.3 MEA Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 16.4 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Country
• 16.5 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Product
• 16.6 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
• 16.7 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
• 16.8 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Application
• 16.9 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
• 16.10 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
• 16.11 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
• 16.12 GCC Respiratory Drug Delivery Market Analysis
• 16.13 South Africa Respiratory Drug Delivery Market Analysis
• 16.14 Egypt Respiratory Drug Delivery Market Analysis
• 16.15 Rest of MEA Respiratory Drug Delivery Market Analysis

17 Company Profiles

• 17.1 Competitive Landscape, 2022
• 17.2 GSK plc
  • 17.2.1 Company Snapshot
  • 17.2.2 Company Overview
  • 17.2.3 Financial Analysis
    • 17.2.3.1 Net Revenue, 2018-2022
    • 17.2.3.2 R&D, 2018-2022
    • 17.2.3.3 Regional Market Shares, 2022
  • 17.2.4 Product Benchmarking
  • 17.2.5 Strategic Outlook
• 17.3 Koninklijke Philips N.V.
  • 17.3.1 Company Snapshot
  • 17.3.2 Company Overview
  • 17.3.3 Financial Analysis
    • 17.3.3.1 Net Revenue, 2018-2022
    • 17.3.3.2 R&D, 2018-2022
    • 17.3.3.3 Segment Market Shares, 2022
    • 17.3.3.4 Regional Market Shares, 2022
  • 17.3.4 Product Benchmarking
  • 17.3.5 Strategic Outlook
• 17.4 3M
  • 17.4.1 Company Snapshot
  • 17.4.2 Company Overview
  • 17.4.3 Financial Analysis
    • 17.4.3.1 Net Revenue, 2018-2022
    • 17.4.3.2 R&D, 2018-2022
    • 17.4.3.3 Segment Market Shares, 2022
    • 17.4.3.4 Regional Market Shares, 2022
  • 17.4.4 Product Benchmarking
  • 17.4.5 Strategic Outlook
• 17.5 Boehringer Ingelheim International GmbH
  • 17.5.1 Company Snapshot
  • 17.5.2 Company Overview
  • 17.5.3 Financial Analysis
    • 17.5.3.1 Net Revenue, 2018-2022
    • 17.5.3.2 Segment Market Shares, 2022
    • 17.5.3.3 Regional Market Shares, 2022
  • 17.5.4 Product Benchmarking
  • 17.5.5 Strategic Outlook
• 17.6 AstraZeneca
  • 17.6.1 Company Snapshot
  • 17.6.2 Company Overview
  • 17.6.3 Financial Analysis
    • 17.6.3.1 Net Revenue, 2018-2022
    • 17.6.3.2 R&D, 2018-2022
    • 17.6.3.3 Segment Market Shares, 2022
    • 17.6.3.4 Regional Market Shares, 2022
  • 17.6.4 Product Benchmarking
  • 17.6.5 Strategic Outlook
• 17.7 Merck & Co., Inc.
  • 17.7.1 Company Snapshot
  • 17.7.2 Company Overview
  • 17.7.3 Financial Analysis
    • 17.7.3.1 Net Revenue, 2018-2022
    • 17.7.3.2 R&D, 2018-2022
    • 17.7.3.3 Segment Market Shares, 2022
    • 17.7.3.4 Regional Market Shares, 2022
  • 17.7.4 Product Benchmarking
  • 17.7.5 Strategic Outlook
• 17.8 Novartis AG
  • 17.8.1 Company Snapshot
  • 17.8.2 Company Overview
  • 17.8.3 Financial Analysis
    • 17.8.3.1 Net Revenue, 2018-2022
    • 17.8.3.2 R&D, 2018-2022
    • 17.8.3.3 Segment Market Shares, 2022
    • 17.8.3.4 Regional Market Shares, 2022
  • 17.8.4 Product Benchmarking
  • 17.8.5 Strategic Outlook
• 17.9 Omron Corporation
  • 17.9.1 Company Snapshot
  • 17.9.2 Company Overview
  • 17.9.3 Financial Analysis
    • 17.9.3.1 Net Revenue, 2018-2022
    • 17.9.3.2 R&D, 2018-2022
    • 17.9.3.3 Segment Market Shares, 2022
    • 17.9.3.4 Regional Market Shares, 2022
  • 17.9.4 Product Benchmarking
  • 17.9.5 Strategic Outlook
• 17.10 Sumitomo Pharma Co., Ltd.
  • 17.10.1 Company Snapshot
  • 17.10.2 Company Overview
  • 17.10.3 Financial Analysis
    • 17.10.3.1 Net Revenue, 2019-2023
    • 17.10.3.2 R&D, 2019-2023
  • 17.10.4 Product Benchmarking
  • 17.10.5 Strategic Outlook
• 17.11 Teva Pharmaceutical Industries Ltd.
  • 17.11.1 Company Snapshot
  • 17.11.2 Company Overview
  • 17.11.3 Financial Analysis
    • 17.11.3.1 Net Revenue, 2018-2022
    • 17.11.3.2 R&D, 2018-2022
    • 17.11.3.3 Regional Market Shares, 2022
  • 17.11.4 Product Benchmarking
  • 17.11.5 Strategic Outlook
• 17.12 Cipla Inc.
  • 17.12.1 Company Snapshot
  • 17.12.2 Company Overview
  • 17.12.3 Financial Analysis
    • 17.12.3.1 Net Revenue, 2019-2023
    • 17.12.3.2 Segment Market Shares, 2023
    • 17.12.3.3 Regional Market Shares, 2023
  • 17.12.4 Product Benchmarking
  • 17.12.5 Strategic Outlook
• 17.13 Medisana GmbH
  • 17.13.1 Company Snapshot
  • 17.13.2 Company Overview
  • 17.13.3 Product Benchmarking
• 17.14 GF Health Products, Inc.
  • 17.14.1 Company Snapshot
  • 17.14.2 Company Overview
  • 17.14.3 Product Benchmarking
• 17.15 AptarGroup, Inc.
  • 17.15.1 Company Snapshot
  • 17.15.2 Company Overview
  • 17.15.3 Financial Analysis
    • 17.15.3.1 Net Revenue, 2018-2022
    • 17.15.3.2 R&D, 2018-2022
    • 17.15.3.3 Segment Market Shares, 2022
    • 17.15.3.4 Regional Market Shares, 2022
  • 17.15.4 Product Benchmarking
  • 17.15.5 Strategic Outlook
• 17.16 Recipharm AB
  • 17.16.1 Company Snapshot
  • 17.16.2 Company Overview
  • 17.16.3 Financial Analysis
    • 17.16.3.1 Net Revenue, 2018-2022
  • 17.16.4 Product Benchmarking
  • 17.16.5 Strategic Outlook
• 17.17 Glenmark Pharmaceuticals Ltd.
  • 17.17.1 Company Snapshot
  • 17.17.2 Company Overview
  • 17.17.3 Financial Analysis
    • 17.17.3.1 Net Revenue, 2018-2022
    • 17.17.3.2 Regional Market Shares, 2022
  • 17.17.4 Product Benchmarking
• 17.18 Vapotherm, Inc.
  • 17.18.1 Company Snapshot
  • 17.18.2 Company Overview
  • 17.18.3 Financial Analysis
    • 17.18.3.1 Net Revenue, 2018-2022
    • 17.18.3.2 R&D, 2018-2022
    • 17.18.3.3 Segment Market Shares, 2022
    • 17.18.3.4 Regional Market Shares, 2022
  • 17.18.4 Product Benchmarking
  • 17.18.5 Strategic Outlook

18 Conclusion and Recommendations

• 18.1 Concluding Remarks from Visiongain
• 18.2 Recommendations for Market Players

관련자료